Querfeld, Christiane
Scarisbrick, Julia J.
Assaf, Chalid
Kim, Youn H.
Guitart, Joan
Quaglino, Pietro
Hodak, Emmilia
Clinical trials referenced in this document:
Documents that mention this clinical trial
Chlormethine Gel Versus Chlormethine Ointment for Treatment of Patients with Mycosis Fungoides: A Post-Hoc Analysis of Clinical Trial Data
https://doi.org/10.1007/s40257-022-00687-y
Documents that mention this clinical trial
Chlormethine Gel Versus Chlormethine Ointment for Treatment of Patients with Mycosis Fungoides: A Post-Hoc Analysis of Clinical Trial Data
https://doi.org/10.1007/s40257-022-00687-y
Funding for this research was provided by:
Helsinn Healthcare SA
Article History
Accepted: 17 March 2022
First Online: 10 May 2022
Declarations
:
: Helsinn Healthcare SA was involved in reviewing of the manuscript according to Good Publication Practices (ExternalRef removed). Writing and editorial assistance was funded by Helsinn Healthcare SA.
: C. Querfeld: Research grant: Celgene; clinical investigator: Helsinn, Celgene, Trillium, miRagen, Bioniz, Kyowa Kirin; advisory board: Helsinn, miRagen, Bioniz, Almirall, Trillium, Kyowa Kirin, Stemline Therapeutics. J.J. Scarisbrick: Consultancy: Takeda, Helsinn, Recordati, 4SC, Kyowa, Mallinckrodt, miRagen; research grant: Kyowa. C. Assaf: Advisory board: 4SC, Takeda, Helsinn, Innate Pharma, Recordati Rare Diseases, Kyowa. Y.H. Kim: Steering committee and research funding: Eisai; research funding: Forty Seven; advisory board member: Seattle Genetics; steering committee member, advisory board, and research funding: Kyowa Hakko Kirin; research funding: Portola, Horizon; research funding: Soligenix; steering committee, advisory board, research funding: Innate; research funding: Elorac; advisory board and research funding: Galderma; steering committee and research funding: Corvus; research funding Trillium. J. Guitart: Research support: Galderma, Soligenix; scientific advisory board: Kyowa Kirin. P. Quaglino: Advisory board: 4SC, Takeda, Actelion, Innate Pharma, Helsinn, Recordati Rare Diseases, Kyowa, Therakos. E. Hodak: Scientific advisory board: Actelion, Helsinn, Recordati Rare Diseases, Takeda; speakers’ bureau: Helsinn, Rafa, Takeda.
: The study protocols were approved by institutional review boards of the participating centers and complied with Good Clinical Practice guidelines and the Declaration of Helsinki.
: All patients provided written informed consent.
: Not applicable.
: Data are available from the corresponding author on reasonable request.
: Not applicable.
: Concept and design: CQ, JJS, CA, YHK, JG, PQ, EH. Drafting of the article or critical revision of the article for important intellectual content: CQ, JJS, CA, YHK, JG, PQ, EH. All authors read and approved the final manuscript.